Kiondo Paul, Wamuyu-Maina Gakenia, Wandabwa Julius, Bimenya Gabriel S, Tumwesigye Nazarius Mbona, Okong Pius
Department of Obstetrics and Gynaecology, School of Medicine, Makerere University College of Health Sciences, P,O Box 7072, Kampala, Uganda.
BMC Pregnancy Childbirth. 2014 Aug 21;14:283. doi: 10.1186/1471-2393-14-283.
Oxidative stress plays a role in the pathogenesis of pre-eclampsia. Supplementing women with antioxidants during pregnancy may reduce oxidative stress and thereby prevent or delay the onset pre-eclampsia. The objective of this study was to evaluate the effect of supplementing vitamin C in pregnancy on the incidence of pre-eclampsia, at Mulago hospital, Kampala, Uganda.
This was a (parallel, balanced randomization, 1:1) placebo randomized controlled trial conducted at Mulago hospital, Department of Obstetrics and Gynecology. Participants included in this study were pregnant women aged 15-42 years, who lived 15 km or less from the hospital with gestational ages between 12-22 weeks. The women were randomized to take 1000mg of vitamin C (as ascorbic acid) or a placebo daily until they delivered. The primary outcome was pre-eclamsia. Secondary outcomes were: severe pre-eclampsia, gestational hypertension, preterm delivery, low birth weight and still birth delivery. Participants were 932 pregnant women randomized into one of the two treatment arms in a ratio of 1:1. The participants, the care providers and those assessing the outcomes were blinded to the study allocation.
Of the 932 women recruited; 466 were randomized to the vitamin and 466 to the placebo group. Recruitment of participants was from November 2011 to June 2012 and follow up was up to January 2013. Outcome data was available 415 women in the vitamin group and 418 women in the placebo group.There were no differences in vitamin and placebo groups in the incidence of pre-eclampsia (3.1% versus 4.1%; RR 0.77; 95% CI: 0.37-1.56), severe pre-eclampsia (1.2% versus 1.0%; RR 1.25; 95% CI: 0.34-4.65), gestational hypertension(7.7% versus 11.5%; RR 0.67; 95% CI: 0.43-1.03), preterm delivery (11.3% versus 12.2%; RR 0.92; 95% CI: 0.63-1.34), low birth weight (11.1% versus 10.3%; RR 1.07; 95% CI: 0.72-1.59) and still birth delivery (4.6% versus 4.5%; RR 1.01; 95% CI: 0.54-1.87).
Supplementation with vitamin C did not reduce the incidence of pre-eclampsia nor did it reduce the adverse maternal or neonatal outcomes. We do not recommend the use of vitamin C in pregnancy to prevent pre-eclampsia.
This study was registered at the Pan African Clinical Trial Registry, PACTR201210000418271 on 25th October 2012.
氧化应激在子痫前期的发病机制中起作用。孕期给女性补充抗氧化剂可能会降低氧化应激,从而预防或延迟子痫前期的发作。本研究的目的是在乌干达坎帕拉的穆拉戈医院评估孕期补充维生素C对子痫前期发病率的影响。
这是一项在穆拉戈医院妇产科进行的(平行、均衡随机分组,1:1)安慰剂随机对照试验。本研究纳入的参与者为年龄在15至42岁之间、居住在距离医院15公里或以内且孕周在12至22周之间的孕妇。这些女性被随机分为每天服用1000毫克维生素C(抗坏血酸)或安慰剂,直至分娩。主要结局是子痫前期。次要结局包括:重度子痫前期、妊娠期高血压、早产、低出生体重和死产。932名孕妇按1:1的比例随机分为两个治疗组之一。参与者、护理人员和评估结局的人员对研究分组情况不知情。
在招募的932名女性中,466名被随机分配到维生素组,466名被分配到安慰剂组。参与者的招募时间为2011年11月至2012年6月,随访至2013年1月。维生素组有415名女性和安慰剂组有418名女性可获得结局数据。维生素组和安慰剂组在子痫前期发病率(3.1%对4.1%;相对危险度0.77;95%可信区间:0.37 - 1.56)、重度子痫前期(1.2%对1.0%;相对危险度1.25;95%可信区间:0.34 - 4.65)、妊娠期高血压(7.7%对11. + 5%;相对危险度0.67;95%可信区间:0.43 - 1.03)、早产(11.3%对12.2%;相对危险度0.92;95%可信区间:0.63 - 1.34)、低出生体重(11. + 1%对10.3%;相对危险度1.07;95%可信区间:0.72 - 1.59)和死产(4.6%对4.5%;相对危险度1.01;95%可信区间:0.54 - 1.87)方面均无差异。
补充维生素C并未降低子痫前期的发病率,也未减少不良的孕产妇或新生儿结局。我们不建议在孕期使用维生素C来预防子痫前期。
本研究于2012年10月25日在泛非临床试验注册中心注册,注册号为PACTR201210000418271。